Biogen shocked by Danish medicines council doubt over Spinraza

New questions from members of the Danish Medicines Council about the effect of Biogen's muscle-wasting treatment Spinraza have caused the decision over whether the treatment should be offered to a wider group to be delayed.

Janne Harder, CEO of Biogen Denmark. | Photo: Biogen Danmark / PR

So close, and yet so far.

Pharmaceutical company Biogen had hoped that yesterday's meeting of the Danish Medicines Council would mean that older children and young people with muscle-wasting disease could also be offered its drug Spinraza as a treatment.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs